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hepatocellular carcinoma (HCC), no effective systemic cytotoxic chemo-
therapy has been established (Lopez et al., 2006). Surgical resection or
percutaneous intervention (radiofrequency ablation and ethanol in-
jection) therapy is effective only at an early stage of HCC. Approximately
70% of these patients develop recurrent tumors within ﬁve years.
Transarterial chemoembolization is reserved for patient intermediate
stageHCCwithout portal invasion or extrahepaticmetastasis.Molecular
target therapy, especially that targeting the angiogenesis pathway, is
now developing as a novel anti-HCC therapy. However to date, none
of these novel has exhibited superior efﬁcacy to sorafenib. Although, so-
rafenib is the only currently available therapeutic option for patients
with advanced-stage HCC, they are required to have a performance sta-
tus of 0–2 and an A Child–Pugh classiﬁcation (Llovet and Bruix, 2008).
Overall, with the currently available diagnostic techniques and thera-
pies, the prognosis of HCC depends on the stage of the disease at the
time of diagnosis and remaining liver function. Thus, lesions detected
at screening must be aggressively investigated because treatment of
early HCC has a high cure rate.
Patients at risk for HCC should undergo surveillance with ultrasonog-
raphy, CT scan, orMRI at 6-monthly intervals. Serum-α-fetoprotein (AFP)
and protein induced vitamin K absence (PIVKA)-II are the most common
markers available to detect HCC. Des gamma carboxyprothrombin (DCP),
AFP-L3 (a glycosylated form of AFP which is produced in higher concen-
tration by HCC than normal liver), Golgi membrane protein 73 (GP73),
and glypican 3 (GPC3) have been proposed as surveillance tests for
HCC. In patients with small tumors or in well-to-moderately differentiat-
ed HCC, serummarkers rarely elevated. Therefore, there is a need for the
development of more sensitive and speciﬁc methods that supplement
these tumor markers for the early detection of HCC. In the past few
years, the potential utility of autoantibody to tumor-associated antigens
(TAA) as cancer biomarker for early detection as indicators of disease
prognosis has been explored. In this issue of EBioMedicine, HongYand col-
leagues investigate the serum autoantibodies to TAA, and identify that
CENPF and HSP 60 were new biomarkers that would add to current
markers and increase the sensitivity and speciﬁcity of early stage of HCCDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.03.010.
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screening populations at high risk of developing HCC, which may lead
to early preventive and therapeutic interventions aimed at suppressing
or slowing the appearance of a tumor.
The most important risk factor for HCC is chronic hepatitis B virus
(HBV) or hepatitis C virus (HCV) infection (El-Serag, 2012). The risk of
HCC is increased 5- to 15-fold in chronic HBV carriers (El-Serag, 2012)
and 11.5- to 17-fold in HCV-infected patients (Donato et al., 2002). In
addition, epidemiological studies have shown that chronic inﬂamma-
tion of the liver predisposes individuals toHCC. Cirrhosis is an additional
risk factor for HCC; the annual risk of HCC is between 1% and 6%.
HBV and HCV infections are now treatable diseases. After a decade
of using PEG2a/RBV to treat chronic hepatitis C patients, telaprevir and
simeprevir, NS3/4A protease inhibitors, co-administered with PEG2a/
RBV were approved for HCV genotype 1 infected patients and demon-
strating signiﬁcant improvements in sustained virological response
(SVR) rates (Jacobson et al., 2011). Recently, asunaprevir and daclatasvir
represent the ﬁrst all oral, interferon free direct-acting anti viral agents
(DAA) containing regimen and are approved for treating patients with
HCV genotype 1 infections. These drugs demonstrate signiﬁcant im-
provements in SVR rateswithout interferon related side-effects. Likewise,
nucleoside analogues are recognized as more effective agents for
chronic hepatitis B patients compared with that of interferon thera-
py. Lamivudine, adefovir (in 2002), entecavir (in 2005), telbivudine (in
2006), and tenofovir disoproxil fumarate (in 2008) have been licensed.
These nucleoside analogues suppress HBV replication through inhibition
of reverse transcriptase and DNA polymerase, and inhibit reverse tran-
scription of pregenomic RNA to HBV DNA. Previous studies have shown
that successful anti-viral therapy can improve biochemical liver function
parameters aswell as histological ﬁndings (Shiratori et al., 2000). Patients
with mild liver ﬁbrosis are likely to show histologically evident decreases
in ﬁbrosis and inﬂammation after a SVR in response to IFN treatment
against HCV infection (Shiratori et al., 2000). Furthermore, treated pa-
tients showmarked reductions in decompensated liver disease and HCC
occurrence (Yoshida et al., 1999; Morgan et al., 2010). Patients with ad-
vanced ﬁbrosis, however, retain relatively low but still considerable
risks ofHCCoccurrencedespite having attained SVR (Morgan et al., 2010).
Risk of HCC development increases in proportion to the degree of
liver ﬁbrosis in patients persistently infected with hepatitis virus. Anti-
viral therapy has been shown to decrease the risk of hepatic decompen-
sation (Morgan et al., 2010) and HCC occurrence (Yoshida et al., 1999)
among sustained virologic responders. In chronic HCV infected patients,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
371K. Yoshida / EBioMedicine 2 (2015) 370–371prevention of unfavorable disease outcome seems most effective when
therapy is given before development of cirrhosis (Morgan et al., 2010).
On the other hand, oral nucleoside analogues are beneﬁcial for patients
with even decompensated HBV-related cirrhosis and HCC (Deng et al.,
2013). Improvement of anti-viral therapy will decrease the incidence
of HCC. However, surveillances to detect HCC at an early stage are still
indispensable to those who achieved SVR. Serum autoantibodies to
TAA can be used as a new predictive biomarker for early assessment
of HCC.
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